<DOC>
	<DOCNO>NCT02416622</DOCNO>
	<brief_summary>This study evaluate safety efficacy recombinant adeno-associated virus vector express retinoschisin ( rAAV2tYF-CB-hRS1 ) patient X-linked retinoschisis . Up 27 participant enrol 3 dose level evaluate dose escalation format .</brief_summary>
	<brief_title>Safety Efficacy rAAV-hRS1 Patients With X-linked Retinoschisis ( XLRS )</brief_title>
	<detailed_description>This non-randomized , open label , Phase 1/2 dose escalation study . Up 27 participant enrol . Each participant receive study agent intravitreal injection one eye single occasion . Enrollment begin low dose proceed high dos review safety data Data Safety Monitoring Committee ( DSMC ) . Participants dose escalation phase ≥ 18 year age . After maximum tolerate dose identified individual ≥ 6 year age enrol . Safety measure number proportion participant experience adverse event immune response RS1 . Efficacy measure evaluation change visual function schisis cavity size .</detailed_description>
	<mesh_term>Retinoschisis</mesh_term>
	<criteria>Inclusion Criteria include : 1 . Retinal disease consistent diagnosis XLRS document mutation RS1 gene 2 . Male individual least 18 year age ( dose escalation phase ) least 6 year age ( maximum tolerate dose phase ) , 3 . Able perform test visual retinal function , 4 . Visual acuity specify group 5 . Not treated CAIs currently within 3 month prior study enrollment , 6 . Have acceptable laboratory parameter . Exclusion Criteria include : 1 . Prior receipt AAV gene therapy product , 2 . Preexisting eye condition would preclude planned intravitreal injection interfere interpretation study endpoint complication vector administration .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>XLRS</keyword>
	<keyword>maculoschisis</keyword>
	<keyword>retinal degeneration</keyword>
	<keyword>RS1</keyword>
	<keyword>adeno-associated virus</keyword>
	<keyword>gene therapy</keyword>
	<keyword>AAV</keyword>
</DOC>